Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Find generic entry opportunities
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Controlled absorption naproxen formulation for once-daily administration|
|Abstract:||A once-daily naproxen formulation for oral administration having a first portion of the naproxen as a multi-particulate pellet form, each pellet having a core of naproxen or a pharmaceutically acceptable salt thereof in association with an organic acid, the core being surrounded by a multi-layer membrane and optionally a second portion of naproxen formulated to release the drug promptly following oral administration.|
|Inventor(s):||Bourke; Edward A. (Athlone, IE), Mulligan; Seamus (Athlone, IE)|
|Assignee:||Elan Corporation, PLC (Athlone, IE)|
Patent Claim Types:|
see list of patent claims
|Formulation; Compound; Dosage form; Device;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Ireland||149/90||Jan 15, 1990|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||126055||<disabled in preview>|
|Australia||639519||<disabled in preview>|
|Australia||6933291||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.